UNMASKING COVISHIELD: THE TRUTH BEHIND VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA

Mr. Sai Shashank Gudla, Mr. Gnanendra Sai Kumar Nareboina

Abstract


The Covishield vaccine, developed by AstraZeneca and the University of Oxford, has been crucial in the global ght against COVID-19. Its
effectiveness in reducing severe disease and hospitalizations has signicantly contributed to public health efforts. Concerns have arisen about
vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with Covishield and other adenoviral vector vaccines. The article
delves into Covishield's development process, clinical trial challenges, and its importance in global vaccination campaigns. It explores the
epidemiology of VITT, noting varying incidence rates across populations and age groups. The pathogenesis of VITT involves antibodies targeting
platelet factor 4 (PF4), offering insights into this rare condition's mechanisms and clinical manifestations like thrombosis and thrombocytopenia.
Controversies surrounding Covishield, particularly VITT cases, are discussed, with ongoing research aiming to understand and mitigate these
risks. The article emphasizes the need to rebuild public trust and the critical role of robust pharmacovigilance systems in monitoring vaccine safety
and efcacy.


Keywords


Covishield, Astrazeneca, Thrombosis, Thrombocytopenia

Full Text:

PDF

References


Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probablebat origin. Nature. 2020;579(7798):270–273.

Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China.

Ministry of Health and Family Welfare. Apr 2021. Available from: https://www.mohfw.gov.in. [Last accessed on 2021 Jul 01]

O'Reilly P (May 2020). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN (Registry). doi:10.1186/ISRCTN89951424. ISRCTN89951424.

AstraZeneca's COVID-19 vaccine: benefits and risks in context". European Medicines Agency (EMA) (Press release). 23 April 2021. Archived from the original on 23 April 2021. Retrieved 23 April 2021.

Mahase E (March 2021). "Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency". BMJ. 372: n774. doi:10.1136/bmj.n774.

Medicines and Healthcare products Regulations Agency. Coronavirus vaccine—summary of Yellow Card. https://tinyurl. com/uwx6jpjh (accessed July 26, 2021).

Menaka Pai.Epidemiology of VITT. Seminars in Hematology. 2022;59:72–75.

Azhar EI, Hui DSC, Memish ZA, et al. The Middle Eastrespiratory syndrome (MERS). Infect Dis Clin NorthAm. 2019;33(4):891–905.

Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine- induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021;43:559-70.

Hunter PR. Thrombosis after covid-19 vaccination. BMJ 2021;373:n958

Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007; 109: 2832–39.

Alba R, Bradshaw AC, Parker AL, et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009; 114: 965–71.

Gupalo E, Kuk C, Qadura M, Buriachkovskaia L, Othman M. Platelet-adenovirus vs inert particles interaction: effect on aggregation and the role of platelet membrane receptors. Platelets 2013; 24: 383–91.

Chan B OA, Jüni P, et al. Risk of vaccine-induced thrombotic thrombocytopenia (VITT) following the AstraZeneca/ COVISHIELD adenovirus vector COVID-19 vaccines. May 11, 2021. https://covid19-sciencetable.ca/sciencebrief/risk-of-vaccineinduced-thrombotic-thrombocytopenia-vitt-following-theastrazeneca-covishield-adenovirus-vector-covid-19-vaccines/ (accessed Sept 12, 2021).

Chatterjee P. Covid-19: India authorises Sputnik V vaccine as cases soar to more than 180 000 a day. BMJ 2021;373:n978.

Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccineinduced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385: 1680–89.

Douxfils J, Favresse J, Dogné JM, et al. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 Jul;203:163–171.

Calcaterra G, Bassareo PP, Barilla’ F, et al. Concerning the unex-pected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown). 2021;6. doi: 10. 2459/JCM.0000000000001232.

Wise J. Covid‐19: how AstraZeneca lost the vaccine PR war.BMJ.2021;373:n921.

Larson HJ, Broniatowski DA. Volatility of vaccine confidence.Science. 2021;371(6536):1289.

Pharmacovigilance Risk Assessment Committee, Rules of Procedure https://www.ema.europa.eu/en/documents/other/prac-rulesprocedure_en.pdf. Accessed 4 Aug 2023.

European Medicines Agency. COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy.https://www.ema.europa.eu/en/news/covid-19-latest-safety-dataprovide-reassurance-about-use-mrna-vaccines-during-pregnancy.Accessed 22 Aug 2023.

Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health: Package inserts and manufacturers for some US licensed vaccines and immunoglobulins. https://www.vaccine-safety.edu/package_inserts.htmuri. Last update June 30, 2020.


Refbacks

  • There are currently no refbacks.